Human papillomavirus negative high grade cervical lesions and cancers: Suggested guidance for HPV testing quality assurance.

ABSTRACT:

Background

Some high-grade cervical lesions and cervical cancers (HSIL+) test negative for human papillomavirus (HPV). The HPV-negative fraction varies between 0.03 % and 15 % between different laboratories. Monitoring and extended re-analysis of HPV-negative HSIL+ could thus be helpful to monitor performance of HPV testing services. We aimed to a) provide a real-life example of a quality assurance (QA) program based on re-analysis of HPV-negative HSIL+ and b) develop international guidance for QA of HPV testing services based on standardized identification of apparently HPV-negative HSIL+ and extended re-analysis, either by the primary laboratory or by a national HPV reference laboratory (NRL).

Methods

There were 116 initially HPV-negative cervical specimens (31 histopathol

SUBMITTER: Pretet JL 

PROVIDER: S-EPMC11863830 | biostudies-literature | 2024 Apr

REPOSITORIES: biostudies-literature